•  
  •  
 

Article Type

Original Study

Abstract

Objective This study aimed to assess the immune response to hepatitis B virus (HBV) vaccine in chronic hemodialysis (HD) patients. Background HBV is an important public health problem in humans. Currently available HB vaccines have an excellent safety and immunogenicity profile. Anti-HBs are the only easily measurable correlate of vaccine-induced protection. Dialyzed patients have impaired immune response and lower seroconversion rates compared with the general population. Patients and methods This study was conducted on 50 patients with chronic renal failure on hemodialysis (HD) and 30 healthy persons. These patients were subjected to full history taking, complete clinical examination, complete blood picture, liver function tests, renal function tests, serum Na, K, and Ca, abdominal and pelvic ultrasound, HBsAg, anti-HBs, anti-HBc, and HCV-Ab by ELISA. Results There was a highly significant decrease in the mean value of anti-HBs titer in the HD group when compared with the control group. In addition, there was a highly significant decrease in the mean value of inadequate anti-HBs titer and a significant decrease in the mean value of adequate anti-HBs titer in the HD group when compared with the control group. A significant negative correlation between anti-HBs titer and age was found. There was a highly significant negative correlation between anti-HBs titer and serum creatinine levels and blood urea. A significant positive correlation between anti-HBs titer and serum albumin levels was found. Conclusion Response of HD patients to HB vaccine is inadequate, with significant negative correlation with serum creatinine, blood urea levels, and age, and a significant positive correlation with serum albumin.

Download

Share

COinS